Author's response to reviews

Title: Predicting for activity of second-line trastuzumab-based therapy in Her2-positive advanced breast cancer

Authors:

Rupert Bartsch (rupert.bartsch@meduniwien.ac.at)
Catharina De Vries (catharina.wenzel@meduniwien.ac.at)
Ursula Pluschnig (ursula.pluschnig@meduniwien.ac.at)
Peter Dubsky (peter.dubsky@meduniwien.ac.at)
Zsuzsanna Bago-Horvath (zsuzsanna.horvath@meduniwien.ac.at)
Simon P Gampenrieder (simon.gampenrieder@meduniwien.ac.at)
Margaretha Rudas (margaretha.rudas@meduniwien.ac.at)
Robert M Mader (robert.mader@meduniwien.ac.at)
Andrea Rottenfusser (andrea.roettenfusser@meduniwien.ac.at)
Christoph Wiltschke (christoph.wiltschke@meduniwien.ac.at)
Michael Gnant (michael.gnant@meduniwien.ac.at)
Christoph C Zielinski (christoph.zielinski@meduniwien.ac.at)
Guenther G Steger (guenther.steger@meduniwien.ac.at)

Version: 4 Date: 12 October 2009

Author's response to reviews: see over
Dear Sir or Madam,

On behalf of all co-authors, we submit a revised version of our manuscript ("Predicting for activity of second-line trastuzumab-based therapy in Her2-positive advanced breast cancer").

We have made all the changes suggested concerning the formatting of the manuscript as well as the figure.

Please further note that payment of the article processing charge for this manuscript (Euro 1,150 + 15% VAT) was supported by an unrestricted grant from Roche Austria GmbH, Vienna, Austria. Accordingly, a statement was included in the acknowledgments section.

Sincerely,

Guenther G. Steger
R. Bartsch